Latest Articles
Comprehensive analyses of telomerase component DKC1 and its association with clinical, molecular and immune landscapes in uterine corpus endometrial carcinoma - Frontiers
Comprehensive analyses of telomerase component DKC1 and its association with clinical, molecular and immune landscapes in uterine corpus endometrial carcinoma Frontiers
Published: May 12, 2025, 7:50 p.m.
DNA glycosylase (NEIL3) overexpression associated with low tumor immune infiltration and poor overall patient survival in endometrial cancer - Nature
DNA glycosylase (NEIL3) overexpression associated with low tumor immune infiltration and poor overall patient survival in endometrial cancer Nature
Published: May 10, 2025, 10:19 a.m.
This Common Condition May Raise Your Risk of Having An Autoimmune Disease By 80%, Study Finds - MSN
This Common Condition May Raise Your Risk of Having An Autoimmune Disease By 80%, Study Finds MSN
Published: May 9, 2025, 12:40 p.m.
This Common Condition May Raise Your Risk of Having An Autoimmune Disease By 80%, Study Finds - Women's Health
This Common Condition May Raise Your Risk of Having An Autoimmune Disease By 80%, Study Finds Women's Health
Published: May 9, 2025, 10:30 a.m.
Endometriosis 101: A Disease Profile - Managed Healthcare Executive
Endometriosis 101: A Disease Profile Managed Healthcare Executive
Published: May 7, 2025, 8:59 p.m.
Endometrial Cancer Phase III Shows Molecular Profiling Personalizes Treatment - Inside Precision Medicine
Endometrial Cancer Phase III Shows Molecular Profiling Personalizes Treatment Inside Precision Medicine
Published: May 7, 2025, 6:12 p.m.
Endometrial Cancer Phase III Shows Molecular Profiling, Personalizes Treatment - Inside Precision Medicine
Endometrial Cancer Phase III Shows Molecular Profiling, Personalizes Treatment Inside Precision Medicine
Published: May 7, 2025, 6:12 p.m.
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - BioSpace
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids BioSpace
Published: May 7, 2025, 1:28 p.m.
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - The Manila Times
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids The Manila Times
Published: May 7, 2025, 12:24 p.m.
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - PR Newswire
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids PR Newswire
Published: May 7, 2025, noon
Link copied to clipboard!